Verona Pharma PLC VRNA.OQ, VRNA.O is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
The London United Kingdom-based company is expected to report revenue of $92.199 million, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Verona Pharma PLC is for a loss of 2 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Verona Pharma PLC is $107.00, about 1.7% above its last closing price of $105.18
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.13 | -0.15 | -0.16 | Missed | -6.7 |
Dec. 31 2025 | -0.20 | -0.29 | -0.40 | Missed | -36.8 |
Sep. 30 2024 | -0.62 | -0.50 | -0.56 | Missed | -12 |
Jun. 30 2024 | -0.37 | -0.29 | -0.88 | Missed | -198.3 |
Mar. 31 2024 | -0.15 | -0.16 | -0.32 | Missed | -95.1 |
Dec. 31 2023 | -0.21 | -0.26 | -0.18 | Beat | 30.8 |
Sep. 30 2023 | -0.30 | -0.28 | -0.18 | Beat | 35.7 |
Jun. 30 2023 | -0.30 | -0.29 | -0.08 | Beat | 72.7 |
This summary was machine generated August 4 at 13:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments